Advertisement

Effects of Cisplatin and Carboplatin on Neurohypophysis, Parathyroid and their Role in Nephrotoxicity

  • S. K. Aggarwal
  • J. M. Fadool
Part of the Developments in Oncology book series (DION, volume 54)

Abstract

Cisplatin (CDDP) is currently one of the most valuable antineoplastic drugs (1) with several toxic side effects of which nephrotoxicity is the major dose limiting factor in its use (2). The primary mechanism of its action has been proposed to be through its cross-linking DNA strands (3). It has also been shown to inactivate various transport enzymes and induce hypocalcemia and hypomagnesemia (4), in addition it causes inhibition of karyokinesis and cytokinesis (5). Cisplatin induces morphological changes in the kidney with hampered urine output depending upon the specie or the strain of animal being used for treatment or testing. Carboplatin (CBDCA) a second generation analogue, however, has proven to be diuretic and less nephrotoxic in some animals. Thus different analogues of platinum have proven to influence the kidney function differently. Cisplatin induces diuresis in Long-Evans rats where as carboplatin is antidiuretic in the same strain of rat (6).

Keywords

Methylene Blue Urine Output Parathyroid Gland Dense Core Vesicle Glycogen Accumulation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Carter, S.K. In: Platinum coordination complexes in cancer chemotherapy (Eds. M.P. Hacker, E.B. Double, and I.H. Krakoff) Martinus Nijhoff Publishing, Boston, pp. 359–396, 1984.Google Scholar
  2. 2.
    Hrushesky, W.J.M. In: Platinum coordination complexes in cancer chemotherapy (Eds. M.P. Hacker, E.B. Double, and I.H. Krakoff), Martinus Nijhoff Publishing, Boston, pp. 165–186, 1984.Google Scholar
  3. 3.
    Zwelling, L.A., Michaels, S., Schwartz, H., Dobson, P.P., and Kohn, K.W. Cancer Res., 41: 640–649, 1981.PubMedGoogle Scholar
  4. 4.
    Aggarwal S.K. and Niroomand-Rad, I. J. Histochem. Cytochem., 31: 307–102, 1983.CrossRefGoogle Scholar
  5. 5.
    Aggarwal, S.K. J. Cell Biol., 83: 327a, 1979.Google Scholar
  6. 6.
    Batzer, M.A. and Aggarwal, S.K.. Cancer Chemother, Pharmacol., 17: 209–217, 1986.CrossRefGoogle Scholar
  7. 7.
    Vassilev, P.M., Kanazirska, M. P., Charamella L.J., Dimitrov, N.V. and Tien, H.T. Cancer Res., 47: 519–522, 1987.PubMedGoogle Scholar
  8. 8.
    Jkeda, H., Nakano, G., Nagashima, K., Sakamoto, K., Harasawa, N., Kitamura, T., Nakamura, T., and Nagamachi, Y. Cancer Res., 47: 231–234, 1987.Google Scholar
  9. 9.
    Aggarwal, S.K., Whitehouse, M.W. and Ramachandran, C. In: Cisplatin: Current concepts and new developments (Eds. A.W. Prestayko, S.T. Crooke, and S.K. Carter), Academic Press, New York, pp. 79–112, 1980.Google Scholar
  10. 10.
    Binet, A. and Volfin, P. Biochimica et Biophysica Acta, 461: 182–187, 1977.PubMedCrossRefGoogle Scholar
  11. 11.
    Nagata, N. and Rasmussen, H. Biochim. Biophys. Acta., 215: 1–16, 1970.PubMedGoogle Scholar
  12. 12.
    Sodhi, A. and Aggarwal, S.K. J. Natl. Cancer Inst., 53: 85–101, 1974.PubMedGoogle Scholar
  13. 13.
    Aggarwal, S.K., Broomhead, J.A., Fairlie, D.P. and Whitehouse, M.W. Cancer Chemother. Pharmacol. 4: 249–258, 1980.PubMedCrossRefGoogle Scholar
  14. 14.
    Wild, P., Bitterli, D. and Becker, M. Lab Invest. 47: 370–374, 1982.PubMedGoogle Scholar
  15. 15.
    Siddik, Z.H., Newell, D.R., Boxall, F.E., Jones, M., McGhee, K.G., Harrap, K.R., In: Platinum coordination complexes in cancer chemotherapy (Eds. M.P. Hacker, E.B. Double and I.H. Krakoff), Martinus Nijhoff Publishing, Boston, pp. 90–102, 1984.Google Scholar
  16. 16.
    Walker, E.M. and Gale, G.R. Ann. Clin. Lab. Sci. 11: 397–410, 1981.PubMedGoogle Scholar
  17. 17.
    Goldstein, R.S., Noorewiew, B., Bond, I.T., Hook, J.B. and Mayor G.H. Toxicol. Appl. Pharmacol. 60: 163–175, 1981.PubMedCrossRefGoogle Scholar
  18. 18.
    Krisch, B. Cell Tiss. Res., 151: 117–140, 1974.CrossRefGoogle Scholar
  19. 19.
    Bambaur, H.J., Ueno, S., Umar, H. and Ueck, M. Cell Tiss. Res. 237: 491–497, 1984.Google Scholar
  20. 20.
    Bajt, M.L. and Aggarwal, S.K. Toxicol. Appl. Pharmacol., 80: 97–107, 1985.PubMedCrossRefGoogle Scholar
  21. 21.
    Keller, K. and Aggarwal, S.K. Toxicol. Appl. Pharmacol., 69: 245–256, 1983.PubMedCrossRefGoogle Scholar
  22. 22.
    Gordon, J.A., Peterson, L.N. and Anderson, R.J. Am. J. Physiol., 243: F36–43, 1982.Google Scholar

Copyright information

© Martinus Nijhoff Publishing, Boston 1988

Authors and Affiliations

  • S. K. Aggarwal
  • J. M. Fadool

There are no affiliations available

Personalised recommendations